{"Title": "Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody\u2013Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study (Ophthalmology and Therapy, (2020), 9, 4, (889-911), 10.1007/s40123-020-00280-8)", "Year": 2020, "Source": "Ophthalmol. Ther.", "Volume": "9", "Issue": 4, "Art.No": null, "PageStart": 913, "PageEnd": 915, "CitedBy": 0, "DOI": "10.1007/s40123-020-00289-z", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85090977975&origin=inward", "Abstract": "\u00a9 2020, The Author(s).The authors of the above mentioned article would like to highlight the following corrections, based upon recent changes to the FDA label and guidance on the use of belamaf. \u2022 Page 3: The second sentence under \u2018\u2018Methods\u2019\u2019 should be \u2018\u2018In brief, eligible patients with RRMM were randomized (1:1) to receive belamaf 2.5- or 3.4-mg/kg every 3 weeks by intravenous infusion over 30 min or longer on day 1 of each cycle.\u2019\u2019 \u2022 Page 5: Table 1, Grade 4, Recommended dose modification currently reads \u2018\u2018Permanently discontinue treatment\u2019\u2019. This should be \u2018\u2018Consider treatment discontinuation for a Grade 4 event. Based on a benefit:risk assessment, if continuing treatment with belamaf is being considered, treatment may be resumed at a reduced dose after the event has improved to Grade 1 or better event.\u2019\u2019 \u2022 Page 6: Table 2, BCVA change, event outcomes as of last follow-up reads \u2018\u201826/44 (48).\u2019\u2019 This should be \u2018\u201826/44 (59)\u2019\u2019. Subjective dry eye, first event outcomes reads \u2018\u20182/14 (31).\u2019\u2019 This should be \u2018\u20182/14 (14)\u2019\u2019. Blurred vision, event outcome as of last follow-up, not recovered reads \u2018\u20189/24 (37).\u2019\u2019 This should be \u2018\u20189/24 (38)\u2019\u2019. \u2022 Page 8, 2nd column, 1st paragraph reads \u2018\u201828% (25/95) of patients\u2019\u2019 this should read \u2018\u201828% (25/88) of patients\u2019\u2019. \u2022 Page 9, 2nd column, first paragraph reads \u2018\u2018Cogan microscysts\u2019\u2019. This should be \u2018\u2018microcysts\u2019\u2019. \u2022 Page 10: Fig. 4 legend, reads \u2018\u2018In vivo confocal microscopic image from the same patient (d\u2013f) demonstrating hyperreflective opacities within the corneal epithelium.\u2019\u2019 This should be \u2018\u2018(c\u2013f)\u2019\u2019. \u2022 Page 10, 2nd column, first paragraph, first sentence reads: \u2018\u2018Following the first dose of belamaf 2.5 mg/kg, he presented on day 27 with MECs characterized as mild/patchy in the periphery/mid-periphery on slit lamp microscopy (Fig. 5a, b). IVCM of the involved areas revealed hyperreflective opacities (Fig. 5c).\u2019\u2019 This should read as \u2018\u2018(Fig. 4a, b)\u2019\u2019 and \u2018\u2018(Fig. 4c\u2013f)\u2019\u2019, respectively. \u2022 Page 18: Under \u2018\u2018Recommended Monitoring, Diagnosis, and Management Techniques\u2019\u2019 and \u2018\u2018Diagnosis and Staging of MECs\u2019\u2019 the final sentence currently reads \u2018\u2018The eye care professional should also determine if the decline in BCVA is related to belamaf-associated examination finding(s).\u2019\u2019 This should be \u2018\u2018Determine the recommended dosage modification of belamaf based on the worst finding in the worst affected eye. Worst finding should be based on either a corneal examination finding or a change in visual acuity per the KVA scale.\u2019\u2019 \u2022 Page 18: Under \u2018\u2018Recommended Monitoring, Diagnosis, and Management Techniques\u2019\u2019 and \u2018\u2018Management\u2019\u2019 the sentence currently reads \u2018\u2018Treatment should be permanently discontinued for a grade 4 event.\u2019\u2019 This should be \u2018\u2018Consider treatment discontinuation for a grade 4 event. Based on a benefit: risk assessment, if continuing treatment with belamaf is being considered, treatment may be resumed at a reduced dose after the event has improved to grade 1 or better event.\u2019\u2019 The original article has been corrected.", "AuthorKeywords": null, "IndexKeywords": null, "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-85090977975", "SubjectAreas": [["Ophthalmology", "MEDI", "2731"]], "AuthorData": {"36445634700": {"Name": "Farooq A.V.", "AuthorID": "36445634700", "AffiliationID": "60011092", "AffiliationName": "University of Chicago Medical Center"}, "57220354179": {"Name": "Jakubowiak A.", "AuthorID": "57220354179", "AffiliationID": "60011092", "AffiliationName": "University of Chicago Medical Center"}, "7003706114": {"Name": "Colby K.", "AuthorID": "7003706114", "AffiliationID": "60011092", "AffiliationName": "University of Chicago Medical Center"}, "56117916000": {"Name": "Degli Esposti S.", "AuthorID": "56117916000", "AffiliationID": "60016691, 60013148", "AffiliationName": "NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology"}, "8645053700": {"Name": "Popat R.", "AuthorID": "8645053700", "AffiliationID": "60024544", "AffiliationName": "University College London Hospitals, NHS Foundation Trust"}, "36570965100": {"Name": "Thulasi P.", "AuthorID": "36570965100", "AffiliationID": "60029586, 60000928", "AffiliationName": "Emory Eye Center, Emory University"}, "26643103100": {"Name": "Lonial S.", "AuthorID": "26643103100", "AffiliationID": "60000928", "AffiliationName": "Emory University, Winship Cancer Institute"}, "6505850659": {"Name": "Nooka A.K.", "AuthorID": "6505850659", "AffiliationID": "60000928", "AffiliationName": "Emory University, Winship Cancer Institute"}, "54961067900": {"Name": "Sborov D.", "AuthorID": "54961067900", "AffiliationID": "60136293, 60025488", "AffiliationName": "Huntsman Cancer Institute, University of Utah"}, "34878093100": {"Name": "Zaugg B.E.", "AuthorID": "34878093100", "AffiliationID": "60012445, 60025488", "AffiliationName": "Moran Eye Center, University of Utah"}, "6701681826": {"Name": "Badros A.Z.", "AuthorID": "6701681826", "AffiliationID": "60012957", "AffiliationName": "University of Maryland School of Medicine"}, "57204579366": {"Name": "Jeng B.H.", "AuthorID": "57204579366", "AffiliationID": "60012957", "AffiliationName": "Department of Ophthalmology and Visual Sciences, University of Maryland School of Medicine"}, "6701433342": {"Name": "Callander N.S.", "AuthorID": "6701433342", "AffiliationID": "60011940, 60032179", "AffiliationName": "University of Wisconsin, Carbone Cancer Center"}, "7801485304": {"Name": "Opalinska J.", "AuthorID": "7801485304", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "57214333672": {"Name": "Baron J.", "AuthorID": "57214333672", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "57214335996": {"Name": "Piontek T.", "AuthorID": "57214335996", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "57218277821": {"Name": "Byrne J.", "AuthorID": "57218277821", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}, "50461642300": {"Name": "Gupta I.", "AuthorID": "50461642300", "AffiliationID": "60097308", "AffiliationName": "GlaxoSmithKline"}}}